暂无相关信息!
[1]HOHMANN T,DEHGHANI F.The cytoskeleton-A complex interacting meshwork [J].Cells,2019,8(4):362.
[2]RUGGIERO C,LALLI E.Targeting the cytoskeleton againstmetastatic dissemination [J].Cancer Metastasis Rev,2021,40(1):89-140.
[3]FRAGLIASSo V,TAMENI A,INGHIRAMI G,et alCytoskeleton dynamics in peripheral T celllymphomas:anntricate network sustaining lymphomagenesis [J].Front Oncol 2021,11:643620.
[4]OSAWA K,NAKANISHI Y,NOGUCHI M,et al.CRMP4s required for the positioning and maturation of newlygenerated neurons in adult mouse hippocampus [J].Neurosci Lett,2022,773:136503.
[5]LUKOMSKA A,THEUNE WC,XING J,et al.Experimentalgene expression of developmentally downregulated Cmpl,Crmp4,and Crmp5 promotes axon regeneration and retinalganglion cell survival afer optic nerve injury [J].Brain Res,2023,1809:148368.
[6]LIANG PI,LAI HY,CHAN TC,et al.Upregulation ofdihydropyrimidinase-like 3 (DPYSL3)protein predicts poorprognosis in urothelial carcinoma [J].BMC Cancer,2023,23(1):599.
[7]NAKAMURA F,OHSHIMA T,GOSHIMA Y.Collapsinresponse mediator proteins:their biological functions andpathophysiology in neuronal development and regeneration [J]Front Cell Neurosci,2020,14:188.
[8]DESPREZ F,UNG DC,VOURCH P,et al.Contributionof the dihydropyrimidinase-like proteins family in synapticphysiology and in neurodevelopmental disorders [J].FrontNeurosci,2023,17:1154446.
[9]TURCK CW,WEBHOFER C,NUSSBAUMER M,et al.Stable isotope metabolic labeling suggests differential turnoverof the DPYSL protein family [J].Proteomics Clin Appl,2016,10(12):1269-1272.
[10]MATSUNUMAR,CHAN DW,KIM BJ,et al.DPYSL3modulates mitosis,migration,and epithelial-to-mesenchymaltransition in claudin-low breast cancer [J].Proe Natl AcadSci USA,2018,115(51):E11978-E11987.
[11]ZHU H,LIN Q,GAO X,et al.Identification of the hubgenes associated with prostate cancer tumorigenesis [J].Front Oncol,2023,13:1168772.
[12]YAMADA Y,ARAI T,SUGAWARA S,et al.Impact ofnovel oncogenic pathwaysregulatedby antitumor miR-451a in renal cell carcinoma [J].Cancer Sci,2018,109(4)1239-1253.
[13]UMETSU S,MIZUKAMI H,SAITO T,et al.Diabetes,an independent poor prognostic factor of non-B non-C hepatocellular carcinoma,correlates with dihydropyrimidinase-like 3 promoter methylation [J].Sci Rep,2020,10(1):1156.
[14]MAO S,MIAO A,CUI Y,et al.Proteomic analysis of retinal conditioned medium:the effect on early differentiation of embryonic stem cells into retina [J].Stem Cells Dev,2022,31(21-22):730-740.
[15]LIU J,ZENG W,LIN Q,et al.Proteomic analyses reveals the mechanism of acupotomy intervention on thetreatment of knee osteoarthritis in rabbits [J].Evid BasedComplement Alternat Med,2022,2022:5698387.
[16]HERRERA-LUIS E,MAK ACY,PEREZ-GARCIA J,et al.Admixture mapping of severe asthma exacerbations inhispanic/latino children and youth [J].Thorax,2023,78(3):233-241.
[17]CANHA-GOUVEIA A,PARADELA A,RAMOS-FERNANDEZA,et al.Which low-abundance proteinsarepresent in the human milieu of gamete/embryo maternalinteraction?[J].Int J Mol Sci,2019,20(21):5305.
[18]NATION JB,CABOT-MILLER J,SEGAL O,et alCombining algorithms to find signatures that predict risk inearly-stage stomach cancer [J].J Comput Biol,2021,28(10):985-1006.
[19]SEKHOACHA M,RIET K,MOTLOUNG P,et al.Prostate cancer review:genetics,dagnosis,treatment options,and alternative approaches[J].Molecules,2022,27(17):5730.
[20]LI B,LI C.Suppresion of prostate cancer metastasis byDPYSL3-targeted saRNA [J].Adv Exp Med Biol,2017,983:207-216.
[21]GAO X,LI LY,RASSLER J,et al.Prospective studyof CRMP4 promoter methylation in prostate biopsies as apredictor for lymph node metastases [J].J Natl Cancer Inst,2017,109(6).
[22]CHEN Z,LIANG Q,WANG J,et al.Collapsin responsemediator protein 4 promotor methylation level as a potentialpredictor for diagnosing primary malignant lymphoma of theprostate[J].Cancer Cell Int,2018,18:3.
[23]GAO X,MAO YH,XIAO C,et al.Calpain-2 triggersprostate cancer metastasis via enhancing CRMP4 promotermethylation through NF-kB/DNMT1 signaling pathway [J]Prostate,2018,78(9):682-690.
[24]GUAN WL,HE Y,XU RH.Gastric cancer treatment:recent progress and future perspectives [J].J Hematol Oncol 2023,16(1):57.
[25]GUO H,XIA B.Collapsin response mediator protein 4isoforms(CRMP4a and CRMP4b)haveopposite effects on cellproliferation,migration,and invasion in gastric cancer [J]BMC Cancer,2016,16:565.
[26]KANDAM,NOMOTOs,OYAH,et al.Dihydropyrimidinase-like 3 facilitates malignant behavior of gastric cancer [J].J Exp Clin Cancer Res,2014,33(1):66.
[27]CHEN S,ZHANG X,PENG J,et alVEGF promotes gastric cancer development by upregulating CRMP4 [J].Oncotarget,2016,7(13):17074-17086.
[28]ZHONG H,LUO x.Serum dihydropyrimidinase-like 3 concentration in patients with gastric cancer and its diagnostic value [J].Iran J Public Health,2021,50(9):1789-1795.
[29]SUNG H,FERLAY J,SIEGEL RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwde for36 cancers in 185 countries [J].CA Cancer J Clin,2021,71(3):209-249.
[30]WON EJ,PARK H,YOON TJ,et al.Gene therapy usingnanocarriers for pancreatic ductal adenocarcinoma:applicationsand challenges in cancer therapeutics [J].Pharmaceutics,2022,14(1):137.
[31]YANAGISAWA R,KOIZUMI T,KOYA T,et alWTl-pulsed dendritic cell vaccine combined with chemotherapyfor resected pancreatic cancer in a phaseI study [J].Anticancer Res,2018,38(4):2217-2225.
[32]HIROSHIMA Y,NAKAMURA F,MIYAMOTO H,et al.Collapsin response mediator protein 4 expression is associatedwith liver metastasis and poor survival in pancreatic cancer [J].Ann Surg Oncol,2013,20Suppl 3:S369-S378.
[33]KAWAHARA T,HOTTA N,OZAWA Y,et al.Quantitative proteomic profiling identifiesDPYSL3 aspancreaticductal adenocarcinoma-associated molecule that regulatescell adhesion and migration by stabilization of focal adhesioncomplex [J].PLoS One,2013,8(12):e79654.
[34]YAZAWA K,NAKAMURA F,MASUKAWA D,et al.Low incidence of high-grade pancreatic intraepithelial neoplasialesions in a crmp4 gene-deficient mouse model of pancreaticcancer [J].Transl Oncol,2020,13(3):100746.
[35]SALEMIF,ALAM W,HASSANI MS,et al.Neuroblastoma:essential genetic pathways and current therapeutic options[J].Eur J Pharmacol,2022,926:175030.
[36]ZHOU x,WANG X,LI N,et al.Therapy resistanceinneuroblastoma;mechanismsand reversal strategies [J].FrontPharmacol,2023,14:1114295.
[37]TAN F,WAHDAN-ALASWAD R,YAN S,et alDihydropyrimidinase-like protein 3 expression is negativelyregulated by MYCN and associated with clinical outcome inneuroblastoma [J].Cancer Sci,2013,104(12):1586-1592
[38]CHICCO D,SANAVIA T,JURMAN G.Signatureliterature review reveals AHCY,DPYSL3,and NME1 asthe most recurrent prognostic genes for neuroblastoma [J].BioData Min,2023,16(1):7.
[39]PANDO A,PATEL AM,CHOUDHRY HS,et al.Pallativecare effects on survival in glioblastoma:whoreceives palliativecare?[J].World Neurosurg,2023,170:e847-e857.
[40]FENG YH,LIM SW,LIN HY,et al.Allopregnanolonesuppresses glioblastoma survival through decreasing DPYSL3and S100A11 expression [J].J Steroid Biochem Mol Biol,2022,219:106067.
[41]LEE E,KAZEROONI EA.Lung cancer screening [J].Semin Respir Crit Care Med,2022,43(6):839-850.
[42]YANG Y,JIANG Y,XIE D,et al.Inhibition of cell-adhesion protein DPYSL3 promotes metasasis of lung cancer [J].Respir Res,2018,19(1):41.
[43]TSAI YM,WU KL,CHANG YY,et al.Upregulation of Thr/Tyr kinase increases the cancer progression by neurotensin and dihydropyrimidinase-like 3 in lung cancer [J].Int J MolSci,2020,21(5):1640.
[44]BABJUK M,BURGER M,CAPOUN O,et al.Europeanassociation of urology guidelines on non-muscle-invasivebladder cancer(Ta,T1,and carcinoma in situ)[J].EurUrol,2022,81(1):75-94.
[45]STASIK S,SALOMO K,HEBERLING U,et al.Evaluation of TERT promoter mutations in urinary cell-freeDNA and sediment DNA for detection of bladder cancer [J]Clin Biochem,2019,64:60-63.
[46]MILLER KD,NOGUEIRA L,DEVASIA T,et al.Cancer treatment and survivorship statistics,2022 [J].CACancer J Clin,2022,72(5):409-436.
[47]LIANG PI,LAI HY,CHAN TC,et al.Upregulation ofdihydropyrimidinase-like 3(DPYSL3)protein predicts poorprognosis in urothelial carcinoma [J].BMC Cancer,2023,23(1):599.
[48]BROWN ZJ,TSILIMIGRAS DI,RUFF SM,et al.Management of hepatocellularcarcinoma:a review [J].JAMASurg,2023,158(4):410-420.
[49]sOV RJ,VERMA BK,WANG H,et al.Virtual clinicaltrials of anti-PD-1 and anti-CTLA-4 immunotherapy inadvanced hepatocellular carcinoma using a quantitative systemspharmacology model [J].J Immunother Cancer,2022,10(11):e005414.
[50]OYA H,KANDA M,SUGIMOTO H,et al.Dihydropyrimidinase-like 3 is a putative hepatocellularcarcinoma tumor suppressor [J].J Gastroenerol,2015,50(5):590-600.
[51]KANDA M,MUROTANI K,SUGIMOTO H,e al.Anintegrated multigene expression panel to predict long-termsurvival after curative hepatectomy in patients with hepatocellularcarcinoma [J].Oncotarget,2017,8(41):71070-71079.
[52]ZHANGC,STAMPFL-MATTERSBERGERM,RUCKSER R,et al.[Colorectal cancer][J].Wien Med Wochenschr,2023,173(9-10):216-220.
[53]ZYGULSKA AL,PIERZCHALSKI P.Novel diagnosticbiomarkers in colorectal cancer [J].Int J Mol Sci,2022,23(2):852.
[54]CHEN SL,CAI SR,ZHANG XH,et al.TargetingCRMP-4 by lentivirus-mediated RNA interference inhibitsSw480 cel poliferation and colorectal cancer growth [J].Exp Ther Med,2016,12(4):2003-2008.
谢峻,施鸿金,毛秋玉,等.二氢嘧啶酶样蛋白3在肿瘤中的表达[J].泌尿外科杂志(电子版),2024,16(02):82-88.DOI:10.20020/j.CNKI.1674-7410.2024.02.14.
暂无相关信息!
近年来,肿瘤生物学功能的研究一直处于肿瘤研究的前沿。细胞骨架动力学一直是支持许多细胞基本过程的重要现象,且在肿瘤发生发展中发挥重要作用[1]。细胞骨架是一个复杂的动态网络,由高度有序的交联丝构成,在细胞形态维持、动力、分裂和细胞内运输等基本细胞过程的控制中起着关键作用[2]。该功能与肿瘤形成密切相关,可促进其异常增殖,表现出不适当的迁移和侵入特征。在实体肿瘤中,细胞骨架与肿瘤特征间的联系已被广泛研究[3]。经研究发现,许多基因参与到细胞骨架的形成中,其中,二氢嘧啶酶样蛋白3(dihydropyrimidinase-like3,DPYSL3)又称塌陷反应调节蛋白4(collapseresponse mediator protein 4,CRMP4),是最常见的参与细胞骨架形成的基因之一,该基因最初发现于中枢神经系统中,其功能为介导神经元突起的生长发育过程,并作为一种潜在治疗靶点用于治疗神经系统损伤与相关疾病[4-5]。但近年来有研究得知,DPYSL3与肿瘤的发生发展有着密切关系,且在不同肿瘤中DPYSL3的表达及预后存在异质性[6]。因此,通过明确DPYSL3与不同肿瘤表达水平间的关系,可为肿瘤的诊断、治疗及预后提供价值,进而为肿瘤相关研究提供理论基础及新思路。本文就DPYSL3结构、生物学功能、分布、调控机制及其在不同肿瘤中表达水平作一综述。
1 DPYSL3结构及其生物学功能
2 DPYSL3的分布
3 DPYSL3在肿瘤中的表达
3.1 前列腺癌
3.2 胃癌
3.3 胰腺癌
3.4 神经母细胞瘤
3.5 胶质母细胞瘤
3.6 肺癌
3.7 尿路上皮癌
3.8 肝细胞癌
3.9 结直肠癌
4 展望与总结
DPYSL3作为一种在神经系统中高表达的胞质磷蛋白,近年来研究发现其在机体内多种肿瘤的表达水平、生物学功能与预后影响方面中存在差异。尽管对DPYSL3的研究已经取得了一些成果,但由于DPYSL3在不同阶段与微环境中可能有不同的表达和功能,其作用机制在很大程度上仍是未知的。本课题组希望进一步研究能够揭示DPYSL3在恶性肿瘤中的作用机制,为肿瘤的治疗提供新的思路。
暂无相关信息!
暂无相关信息!